ThromboGenics

ThromboGenics

ThromboGenics

Delivering next gen treatments for vitreo-retinal disorders, focus on diabetic eye disease. Pioneering pharmacological vitreolysis globally (ocriplasmin owner).
Follow us
Alexa global traffic share
Twitter followers
Team Size
50+
Employees
Location
Headquarters

No recent coverage

Index constantly checks hot and trending companies for their latest activity. We haven't gotten to this company yet, but if you follow it you'll be the the first to know when ThromboGenics makes some noise.